Sirio Pharma Co., Ltd.

Equities

300791

CNE100003NB0

Food Processing

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
40.94 CNY -0.15% Intraday chart for Sirio Pharma Co., Ltd. -1.80% +18.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sirio Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Sirio Pharma Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Sirio Pharma Co., Ltd.'s Equity Buyback announced on September 15, 2023, has closed with 1,285,600 shares, representing 0.71% for CNY 39.9 million. CI
Tranche Update on Sirio Pharma Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A-Shares of Sirio Pharma Company Limited are subject to a Lock-Up Agreement Ending on 25-SEP-2023. CI
Sirio Pharma Co., Ltd.(XSEC:300791) added to S&P Global BMI Index CI
Sirio Pharma Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares. CI
Sirio Pharma Co., Ltd. authorizes a Buyback Plan. CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023 CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sirio Pharma Co., Ltd. Proposes Profit Distribution Proposal of Cash Dividend for the Year 2022 CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sirio Pharma Co., Ltd.(XSEC:300791) dropped from S&P Global BMI Index CI
Sirio Pharma Cancels Planned 1.35 Billion Yuan Share Sale to Fund Aquisition MT
Sirio Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Sirio Pharma Co., Ltd. acquired 80% stake in Best Formulations Inc. from m Eugene C. Ung, Kelly C. Ung, Charles C. Ung, Peak Trust Company-NV, Jeffrey A. Goh, and Joy S. Hsu. CI
Certain A-Shares of Sirio Pharma Company Limited are subject to a Lock-Up Agreement Ending on 25-SEP-2022. CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Sirio Pharma to Buy 80% of US Rival Best Formulations for $180 Million; Shares Slump 4% MT
Sirio Pharma Plans to Raise Up to CNY 1.35 Billion in Share Private Placement CI
Sirio Pharma Co., Ltd. agreed to acquire 80% stake in Ultimate Formulations, Inc. CI
Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding CI
Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022 CI
Chart Sirio Pharma Co., Ltd.
More charts
Sirio Pharma Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of nutritional health food. The Company's main products include soft capsules, tablets, powders, soft candy, hard capsules and oral liquids. The Company's own brand is WEWOW nutritional health food. The Company distributes its products both in the domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
40.94 CNY
Average target price
41.67 CNY
Spread / Average Target
+1.77%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300791 Stock
  4. News Sirio Pharma Co., Ltd.
  5. Sirio Pharma Cancels Planned 1.35 Billion Yuan Share Sale to Fund Aquisition
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW